EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CG Oncology's enterprise value is $1,759.64 Mil.
CG Oncology's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.53 Mil. Therefore, CG Oncology's EV-to-Revenue for today is 3,320.07.
The historical rank and industry rank for CG Oncology's EV-to-Revenue or its related term are showing as below:
CGON'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1070.79 Med: 6953.19 Max: 16222.65
Current: 3320.07
During the past 3 years, the highest EV-to-Revenue of CG Oncology was 16222.65. The lowest was 1070.79. And the median was 6953.19.
CGON's EV-to-Revenue is ranked worse than 97.69% of 1039
companies
in the Biotechnology industry
Industry Median: 7.94
vs CGON: 3320.07
As of today (2024-06-07), CG Oncology's stock price is $34.90.
CG Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.01. Therefore, CG Oncology's PS Ratio for today is 3,172.73.
CG Oncology EV-to-Revenue Historical Data
The historical data trend for CG Oncology's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CG Oncology's EV-to-Revenue
For the Biotechnology subindustry, CG Oncology's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CG Oncology's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CG Oncology's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where CG Oncology's EV-to-Revenue falls into.
CG Oncology's current Enterprise Value is $1,759.64 Mil.
CG Oncology's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CG Oncology's share price for today is $34.90.
CG Oncology's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CG Oncology EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of CG Oncology's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CGON has been successfully added to your